Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Osteoporosis: HELP
Articles by George Lyritis
Based on 7 articles published since 2010
(Why 7 articles?)

Between 2010 and 2020, George Lyritis wrote the following 7 articles about Osteoporosis.
+ Citations + Abstracts
1 Review A contemporary therapeutic approach to bone disease in beta-thalassemia - a review. 2018

Stefanopoulos, Dimitrios / Papaioannou, Nikolaos A / Papavassiliou, Athanassios G / Mastorakos, George / Vryonidou, Andromachi / Michou, Aikaterini / Dontas, Ismene A / Lyritis, George / Kassi, Eva / Tournis, Symeon. ·Laboratory for Research of the Musculoskeletal System "Th. Garofalidis", KAT Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. · Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. · Second Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Aretaieion Hospital, Athens, Greece. · Department of Endocrinology, Diabetes & Metabolism, General Hospital Korgialenio-Benakio, Athens, Greece. · Deparment of Endocrinology, "Elena Venizelou" General Hospital, Athens, Greece. · Hellenic Osteoporosis Foundation, Athens, Greece. · First Department of Internal Medicine - Medical School- Laikon Hospital - National and Kapodistrian University of Athens, Greece. ·J Frailty Sarcopenia Falls · Pubmed #32300690.

ABSTRACT: Homozygous beta-thalassemia represents a serious hemoglobinopathy, in which an amazing prolongation in the survival rate of patients has been achieved over recent decades. A result of this otherwise positive evolution is the fact that bone problems have become a major issue in this group of patients. Through an in-depth review of the related literature, the purpose of this study is to present and comment on the totality of the data that have been published to date pertaining to the prevention and treatment of thalassemia bone-disease, focusing on: the contribution of diet and lifestyle, the treatment of hematologic disease and its complications, the management of hypercalciuria, the role of vitamins and minerals and the implementation of anti-osteoporosis medical regimen. In order to comprehensively gather the above information, we mainly reviewed the international literature through the PubMed database, searching for the preventive and therapeutic data that have been published pertaining to thalassemia bone-disease over the last twenty-nine years. There is no doubt that thalassemia bone-disease is a complication of a multi-factorial etiopathology, which does not follow the rules of classical postmenopausal osteoporosis. Bisphosphonates have been the first line of treatment for many years now, with varied and usually satisfactory results. In addition, over the last few years, more data have arisen for the use of denosumab, teriparatide, and other molecules that are in the clinical trial phase, in beta-thalassemia.

2 Article Degenerative inter-vertebral disc disease osteochondrosis intervertebralis in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over. 2017

Armbrecht, Gabriele / Felsenberg, Dieter / Ganswindt, Melanie / Lunt, Mark / Kaptoge, Stephen K / Abendroth, Klaus / Aroso Dias, Antonio / Bhalla, Ashok K / Cannata Andia, Jorge / Dequeker, Jan / Eastell, Richard / Hoszowski, Krzysztof / Lyritis, George / Masaryk, Pavol / van Meurs, Joyce / Miazgowski, Tomasz / Nuti, Ranuccio / Poór, Gyula / Redlund-Johnell, Inga / Reid, David M / Schatz, Helmut / Todd, Christopher J / Woolf, Anthony D / Rivadeneira, Fernando / Javaid, Muhammad K / Cooper, Cyrus / Silman, Alan J / O'Neill, Terence W / Reeve, Jonathan / Anonymous5221111. ·Department of Radiology and Nuclear Medicine, Free University, Berlin, Germany. · NIHR Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, & Arthritis Research UK Centre for Epidemiology, Manchester, University of Manchester. · Department of Public Health and Primary Care, Strangeways Research Laboratory, Cambridge, UK. · Klinik fur Innere Medezin IV, Jena, Germany. · Rheumatology, Hospital de San Joao, Oporto, Portugal. · Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK. · Nephrology, Asturias General Hospital, Oviedo, Spain. · Rheumatology, University Hospital, Leuven, Belgium. · Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK. · Medicine, PKP Hospital, Warsaw, Poland. · Laboratory for the Research of Musculoskeletal System, University of Athens, Athens, Greece. · Rheumatology, Institute of Rheumatic Diseases, Piestany, Slovakia. · Department of Epidemiology and Department of Internal Medicine, Erasmus University, Rotterdam, Netherlands. · Department of Hypertension and Internal Medicine, Pomeranian Medical University, Szczecin, Poland. · Institute of Clinical Medicine, University of Siena, Siena, Italy. · 1st Department of Rheumatology and Metabolic Osteology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary. · Orthopaedics and Radiology, Malmö General Hospital, Malmö, Sweden. · School of Medicine, Medical Science and Nutrition, University of Aberdeen, Aberdeen, UK. · Rheumatology, Med Klinik & Polyklinik, Bochum, Germany. · School of Health Sciences, The University of Manchester, Oxford Road, Manchester. · Institute of Health Care Research, Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth, Royal Cornwall Hospital, Truro. · Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, NIHR Musculo-skeletal Biomedical Research Unit, Botnar Research Centre, Oxford, UK. ·Rheumatology (Oxford) · Pubmed #28398504.

ABSTRACT: Objectives: To assess the prevalences across Europe of radiological indices of degenerative inter-vertebral disc disease (DDD); and to quantify their associations with, age, sex, physical anthropometry, areal BMD (aBMD) and change in aBMD with time. Methods: In the population-based European Prospective Osteoporosis Study, 27 age-stratified samples of men and women from across the continent aged 50+ years had standardized lateral radiographs of the lumbar and thoracic spine to evaluate the severity of DDD, using the Kellgren-Lawrence (KL) scale. Measurements of anterior, mid-body and posterior vertebral heights on all assessed vertebrae from T4 to L4 were used to generate indices of end-plate curvature. Results: Images from 10 132 participants (56% female, mean age 63.9 years) passed quality checks. Overall, 47% of men and women had DDD grade 3 or more in the lumbar spine and 36% in both thoracic and lumbar spine. Risk ratios for DDD grades 3 and 4, adjusted for age and anthropometric determinants, varied across a three-fold range between centres, yet prevalences were highly correlated in men and women. DDD was associated with flattened, non-ovoid inter-vertebral disc spaces. KL grade 4 and loss of inter-vertebral disc space were associated with higher spine aBMD. Conclusion: KL grades 3 and 4 are often used clinically to categorize radiological DDD. Highly variable European prevalences of radiologically defined DDD grades 3+ along with the large effects of age may have growing and geographically unequal health and economic impacts as the population ages. These data encourage further studies of potential genetic and environmental causes.

3 Article Prospective study of spinal orthoses in women. 2015

Dionyssiotis, Yannis / Trovas, Georgios / Thoma, Sofia / Lyritis, George / Papaioannou, Nikolaos. ·University of Athens, Athens, Greece yannis_dionyssiotis@hotmail.com. · University of Athens, Athens, Greece. ·Prosthet Orthot Int · Pubmed #25138115.

ABSTRACT: BACKGROUND: There are not many clinical trials investigating the efficiency and compliance of using spinal orthoses in the management of osteoporosis. OBJECTIVES: The purpose of this study was to investigate the effect of long-term use and the compliance of spinal orthoses in postmenopausal women with vertebral fractures. STUDY DESIGN: Clinical trial of spinal orthoses in postmenopausal women. METHODS: Women were separated into groups wearing different types of orthoses (Spinomed, Osteomed, Spinomed active, and Spine-X). Isometric maximum strength of trunk muscles (F/Wabdominals-extensors) was calculated and back pain was assessed in all women. In addition, women completed a compliance questionnaire about the use of the orthoses. RESULTS: Spinomed decreased pain (p = 0.001) and increased trunk muscle strength (F/Wabdominals, p = 0.005 and F/Wextensors, p = 0.003, respectively). The compliance of wearing an orthosis for 6 months was 66%. CONCLUSION: The results suggest that orthoses could be an effective intervention for back pain and muscle strengthening in osteoporotic women. CLINICAL RELEVANCE: In women with established osteoporosis, wearing Spinomed orthosis for at least 2 h/day for 6 months decreased back pain significantly and increased personal isometric trunk muscle strength. All spinal orthoses could be valuable instruments to help all requested rehabilitation programs like spine muscles' strengthening and postural correct behavior, but only when used properly.

4 Article Severe osteoporosis and mutation in NOTCH2 gene in a woman with Hajdu-Cheney syndrome. 2013

Stathopoulos, Ioannis P / Trovas, George / Lampropoulou-Adamidou, Kalliopi / Koromila, Theodora / Kollia, Panagoula / Papaioannou, Nikolaos A / Lyritis, George. ·Laboratory for Research of Musculoskeletal System Theodoros Garofalidis, University of Athens, KAT hospital, Athens, Greece. ipstathopoulos@gmail.com ·Bone · Pubmed #23117206.

ABSTRACT: Hajdu-Cheney syndrome (HCS) is a rare genetic disorder characterised by acro-osteolysis, skull deformation and generalised osteoporosis. Recently, truncating mutations in the last exon of NOTCH2, a protein-coding gene, were found to be responsible. We present the case of a young woman with HCS in whom clinical and radiologic diagnosis was confirmed with DNA tests.

5 Article Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. 2012

Adami, Silvano / Libanati, Cesar / Boonen, Steven / Cummings, Steven R / Ho, Pei-Ran / Wang, Andrea / Siris, Ethel / Lane, Joseph / Anonymous3570740 / Adachi, Jonathan D / Bhandari, Mohit / de Gregorio, Luiz / Gilchrist, Nigel / Lyritis, George / Möller, Gerd / Palacios, Santiago / Pavelka, Karel / Heinrich, Resch / Roux, Christian / Uebelhart, Daniel. ·Faculty of Medicine & Surgery, University of Verona, P. le Scuro 10, 37134, Verona, Italy. ·J Bone Joint Surg Am · Pubmed #23097066.

ABSTRACT: BACKGROUND: Fracture is the major complication of osteoporosis, and it allows the identification of individuals needing medical intervention for osteoporosis. After nonvertebral fracture, patients often do not receive osteoporosis medical treatment despite evidence that this treatment reduces the risk of subsequent fracture. In this pre planned analysis of the results of the three-year, placebo-controlled FREEDOM trial, we evaluated the effect of denosumab administration on fracture-healing to address theoretical concerns related to initiating or continuing denosumab therapy in patients presenting with a nonvertebral fracture. METHODS: Postmenopausal women aged sixty to ninety years with osteoporosis were randomized to receive 60 mg of denosumab (n = 3902) or a placebo (n = 3906) subcutaneously every six months for three years. Investigators reported complications associated with a fracture or its management and with fracture-healing for all nonvertebral fractures that occurred during the study. Delayed healing was defined as incomplete fracture-healing six months after the fracture. RESULTS: Six hundred and sixty-seven subjects (303 treated with denosumab and 364 who received a placebo) had a total of 851 nonvertebral fractures (386 in the denosumab group and 465 in the placebo group), including 199 fractures (seventy-nine in the denosumab group and 120 in the placebo group) that were treated surgically. Delayed healing was reported in seven subjects (two in the denosumab group and five in the placebo group), including one with subsequent nonunion (in the placebo group). Neither delayed healing nor nonunion was observed in any subject who had received denosumab within six weeks preceding or following the fracture. A complication associated with the fracture or intervention occurred in five subjects (2%) and twenty subjects (5%) in the denosumab and placebo groups,respectively (p = 0.009). CONCLUSIONS: Denosumab in a dose of 60 mg every six months does not seem to delay fracture-healing or contribute to other complications, even when it is administered at or near the time of the fracture.

6 Article Changes in parameters of bone metabolism in postmenopausal women following a 12-month intervention period using dairy products enriched with calcium, vitamin D, and phylloquinone (vitamin K(1)) or menaquinone-7 (vitamin K (2)): the Postmenopausal Health Study II. 2012

Kanellakis, Spyridon / Moschonis, George / Tenta, Roxane / Schaafsma, Anne / van den Heuvel, Ellen G H M / Papaioannou, Nikolaos / Lyritis, George / Manios, Yannis. ·Department of Nutrition and Dietetics, Harokopio University, Kallithea, Athens, Greece. ·Calcif Tissue Int · Pubmed #22392526.

ABSTRACT: The objective of the present study was to examine the effect of dairy products enriched with calcium, vitamin D(3), and phylloquinone (vitamin K(1)) or menaquinone-7 (vitamin K(2)) on parameters of bone metabolism in postmenopausal women following a 12-month intervention. Postmenopausal women were divided into three intervention groups and a control group (CG). All three intervention groups attended biweekly sessions and received fortified dairy products providing daily 800 mg of calcium and 10 μg of vitamin D(3) (CaD). Furthermore, in two of the three intervention groups the dairy products were also enriched with vitamin K, providing daily 100 μg of either phylloquinone (CaDK1) or menaquinone-7 (CaDK2). The increase observed for serum 25(OH)D levels in all intervention groups and the increase observed for serum IGF-I levels in the CaDK2 group differed significantly compared to the changes observed in CG (P = 0.010 and P = 0.028, respectively). Furthermore, both the CaDK1 and CaDK2 groups had a significantly lower mean serum undercarboxylated osteocalcin to osteocalcin ratio and urine deoxypyridinoline levels at follow-up compared to the CaD and CG groups (P = 0.001 and P = 0.047, respectively). Significant increases in total-body BMD were observed in all intervention groups compared to CG (P < 0.05), while significant increases in lumbar spine BMD were observed only for CaDK1 and CaDK2 compared to CG (P < 0.05) after controlling for changes in serum 25(OH)D levels and dietary calcium intake. In conclusion, the present study revealed more favorable changes in bone metabolism and bone mass indices for the two vitamin K-supplemented groups, mainly reflected in the suppression of serum levels of bone remodeling indices and in the more positive changes in lumbar spine BMD for these two study groups.

7 Article Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. 2010

Lyritis, George / Marin, Fernando / Barker, Clare / Pfeifer, Michael / Farrerons, Jordi / Brixen, Kim / del Pino, Javier / Keen, Richard / Nickelsen, Thomas N / Anonymous3150661. ·University of Athens, Greece. ·Curr Med Res Opin · Pubmed #20482322.

ABSTRACT: OBJECTIVE: To investigate changes in back pain in postmenopausal women with severe osteoporosis who received teriparatide for 24 months or switched at 12 months to raloxifene or no active treatment. STUDY DESIGN AND METHODS: This prospective, controlled, randomised, open-label, 2-year study enrolled 868 postmenopausal women with osteoporosis and a recent fragility fracture. After 12 months of teriparatide (20 microg/day), 507 patients were randomised to further teriparatide (n = 305), raloxifene 60 mg/day (n = 100), or no active treatment (n = 102) for another 12 months (substudy 1); in substudy 2, 199 patients continued teriparatide. All received calcium and vitamin D supplementation. Back pain was self-assessed by patients using a visual analogue scale (0-100 mm). Changes in back pain were analysed using a mixed model for repeated measures. RESULTS: During year 1, back pain decreased from a mean (SD) of 48.9 mm (24.0) at baseline by 11.5 mm (p < 0.001) in the total study population. In substudy 1, mean change in back pain from month 12 (randomisation) to 24 months was -2.2, -4.4 and +0.7 mm in the teriparatide (p = 0.076), raloxifene (p = 0.041), and no active treatment groups (p = 0.751). There were no between-group differences from randomization to 18 or 24 months. In a sensitivity analysis excluding patients with low baseline back pain (VAS < 30 mm), mean change from randomisation to endpoint was significant for teriparatide (-3.9 mm, p = 0.006) and raloxifene (-6.3 mm, p = 0.018) groups. Subgroup analyses of 503 patients who received teriparatide for up to 2 years showed that patients with a recent vertebral fracture had a greater decrease in back pain than those without (p < 0.05). Those with and without mild back pain (>or=30 mm), and those with and without severe back pain (>or=60 mm) at baseline all had a statistically significant reduction in back pain after 24 months (p < 0.05). CONCLUSIONS: Teriparatide treatment is associated with significant reductions in back pain regardless of the presence of recent vertebral fracture. These results need to be considered with caution due to the open-label design of the study.